It has also been suggested that alpha-fetoprotein (AFP) may be used as a marker for HCC CSCs, as seen by elevated levels of stem cell markers and EpCAM in AFP+ patient-derived tumors [105]. This evidence concerns the gene EPCAM and hepatocellular carcinoma.